Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

• Published in: Cephalalgia Vol. 39; no. 1; pp. 100 - 110
• Main Authors: de Hoon, Jan, Van Hecken, Anne, Vandermeulen, Corinne, Herbots, Marissa, Kubo, Yumi, Lee, Ed, Eisele, Osa, Vargas, Gabriel, Gabriel, Kristin
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2019
• Subjects: Adult; Antibodies, Monoclonal, Humanized - pharmacology; Blood Pressure - drug effects; Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Migraine Disorders - drug therapy; Original; Serotonin 5-HT1 Receptor Agonists - pharmacology; Sumatriptan - pharmacology; clinical trial; blood pressure; migraine; safety; pharmacokinetics; Erenumab; sumatriptan

Objectives The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. Methods In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controlled...